ライフサイエンスコーパス: pneumonitis

1 , grade 2 hyperthyroidism, recurrent grade 4 pneumonitis).

2 b, and one treatment-related death occurred (pneumonitis).

3 irl with fire-eater's pneumonia (hydrocarbon pneumonitis).

4 of patients) occurred, each associated with pneumonitis.

5 TH17-mediated lung disease, hypersensitivity pneumonitis.

6 tive pulmonary disease, and hypersensitivity pneumonitis.

7 rectivirgula in a model of hypersensitivity pneumonitis.

8 nic rejection after IS withdrawal because of pneumonitis.

9 the treatment of a mouse model of autoimmune pneumonitis.

10 of fibrosis in experimental hypersensitivity pneumonitis.

11 One patient in each arm had fatal pneumonitis.

12 gen exposure known to cause hypersensitivity pneumonitis.

13 d adequate organ function, and no history of pneumonitis.

14 e of IL-17A in experimental hypersensitivity pneumonitis.

15 tial pneumonia, and chronic hypersensitivity pneumonitis.

16 mortality in a CD8+ T cell-specific model of pneumonitis.

17 , consistent with more severe alveolitis and pneumonitis.

18 II BMT mice are only modestly protected from pneumonitis.

19 8% grade 3 esophagitis, and 7% grade 3 to 4 pneumonitis.

20 ly ill patients and can lead to pneumonia or pneumonitis.

21 kine in fibrotic disease and likely promotes pneumonitis.

22 ontrol microbial Ag-induced hypersensitivity pneumonitis.

23 mucositis; however, four patients developed pneumonitis.

24 odel of B. subtilis-induced hypersensitivity pneumonitis.

25 had grade 3 toxicities including one grade 3 pneumonitis.

26 rom SARS-CoV-infected aged mice that develop pneumonitis.

27 utation developed autoimmune myocarditis and pneumonitis.

28 ration pneumonia or non-bacterial aspiration pneumonitis.

29 There were no cases of radiation pneumonitis.

30 One patient died due to ADV pneumonitis.

31 ival in people with chronic hypersensitivity pneumonitis.

32 s, catheter-related infections, and possible pneumonitis.

33 cells and protect mice from fatal autoimmune pneumonitis.

34 umber of HLA mismatches, and cytomegalovirus pneumonitis.

35 ctions, acute rejection, and cytomegalovirus pneumonitis.

36 ologic features consistent with interstitial pneumonitis.

37 ents died from probable radiation-associated pneumonitis.

38 f lung injury to a neutrophilic interstitial pneumonitis.

39 he beta3-/-LDLR-/- mice due to noninfectious pneumonitis.

40 a case each of cytomegalovirus retinitis and pneumonitis.

41 r, malaise, cough, dyspnea, and interstitial pneumonitis.

42 ldren with cellular nonspecific interstitial pneumonitis.

43 al desquamative and nonspecific interstitial pneumonitis.

44 ction with the C. trachomatis agent of mouse pneumonitis.

45 sen based on the estimated risk of radiation pneumonitis.

46 cause of morbidity and mortality from viral pneumonitis.

47 he 49 patients with non-bacterial aspiration pneumonitis.

48 ical but severe varicella-zoster virus (VZV) pneumonitis.

49 d safe in T cell-deficient patients with RSV pneumonitis.

50 ly infected with C. trachomatis strain mouse pneumonitis.

51 occurred over time in patients who developed pneumonitis.

52 , albeit with a potential high risk of fatal pneumonitis.

53 8% (95% CI, 0.4%-1.2%) for grade 3 or higher pneumonitis.

54 .6%; P < .001) but not for grade 3 or higher pneumonitis.

55 rse events (AEs); 7% of patients (n = 4) had pneumonitis.

56 sensory neuropathy, and one case of grade 4 pneumonitis.

57 of the scurfy donor, including hepatitis and pneumonitis.

58 ilimumab 1 mg/kg died from treatment-related pneumonitis.

59 including one patient from bleomycin-induced pneumonitis.

60 are no biomarkers that can predict radiation pneumonitis.

61 ed and were attributed to treatment-emergent pneumonitis.

62 signaling and protect from bleomycin-induced pneumonitis.

63 PAR1 to ERK, and inhibits bleomycin-induced pneumonitis.

64 in the use of CT or PET to predict radiation pneumonitis.

65 had higher rates of grade 2 or greater acute pneumonitis (1.2% vs. 0.2%, P=0.01) and lymphedema (8.4%

66 .6% vs 1.6%; P < .001) and grade 3 or higher pneumonitis (1.5% vs 0.2%; P = .001) in melanoma, with 1

67 .1% vs 1.6%; P = .002) and grade 3 or higher pneumonitis (1.8% vs 0.2%; P < .001) compared with melan

68 ncluded transient hypoxemia (19%), radiation pneumonitis (11%), and fatigue (4%).

69 fever (21%), hemorrhagic cystitis (12%), and pneumonitis (11%).

70 11%; P = .03]), while rates of grade 3 to 4 pneumonitis (12% vs 9%; P = .12) and esophagitis (23% vs

71 ctions and/or bacteremia (16%), and possible pneumonitis (18%).

72 cemia (4% vs. <1%), fatigue (4% vs. 1%), and pneumonitis (3% vs. 0%).

73 acute respiratory distress syndrome (5.7%), pneumonitis (3.8%), and atrial fibrillation (2.9%).

74 daily group; p=0.85) and grade 3-4 radiation pneumonitis (4 [3%] of 254 vs 4 [2%] of 246; p=0.70).

75 CC was higher than in melanoma for all-grade pneumonitis (4.1% vs 1.6%; P < .001) but not for grade 3

76 Autoimmune events included pneumonitis (6 [13%]) and hypothyroidism (5 [10%]), most

77 e (15%), muscle weakness (6%), anxiety (6%), pneumonitis (6%), and rash (6%).

78 IMRT was associated with less >/= grade 3 pneumonitis (7.9% v 3.5%, P = .039) and a reduced risk i

79 ncluded liver function test elevation (14%), pneumonitis (9%), diarrhea (4%), nausea (4%), fatigue (4

80 xel included febrile neutropenia (10.9%) and pneumonitis (9.6%); 28.8% of patients were hospitalized

81 n increase of 1.92 in the odds ratio for CMV pneumonitis (95% confidence interval 1.03-3.56).

82 d a multifocal mononuclear cell interstitial pneumonitis, accompanied by multinucleated syncytial cel

83 Three deaths were attributed to treatment (pneumonitis, acute respiratory failure, and cardiovascul

84 gy consisting of alveolitis and interstitial pneumonitis after a live-virus challenge.

85 We conclude that the risk of CMV pneumonitis after lung transplantation is related to the

86 L/6, BALB/c, and C3H/HeN mice with the mouse pneumonitis agent of C. trachomatis (MoPn).

87 Vaginal infection with the mouse pneumonitis agent of Chlamydia trachomatis (MoPn) produc

88 course of a murine infection with the mouse pneumonitis agent of Chlamydia trachomatis (MoPn).

89 pare the incidence of PD-1 inhibitor-related pneumonitis among different tumor types and therapeutic

90 withdrawal syndrome and sirolimus-associated pneumonitis and arthralgia.

91 RT was associated with lower rates of severe pneumonitis and cardiac doses in NRG Oncology clinical t

92 ed, including adults with usual interstitial pneumonitis and children with cellular nonspecific inter

93 athological findings, including interstitial pneumonitis and consolidation, is also remarkably reduce

94 e IPF compared with nonspecific interstitial pneumonitis and controls, which rose sharply during an a

95 in an enhanced immune-mediated interstitial pneumonitis and delayed clearance of SARS-CoV from the l

96 diotherapy is a mainstay for cancer therapy, pneumonitis and fibrosis constitute dose-limiting side e

97 ave also developed a mitigator for radiation pneumonitis and fibrosis that can be started as late as

98 of treatment-related adverse events (grade 4 pneumonitis and grade 4 thrombocytopenia) and subsequent

99 fection with the Chlamydia trachomatis mouse pneumonitis and L3 serovars and to Chlamydia pneumoniae.

100 th non-tuberculosis pulmonary hypersensitive pneumonitis and Mycobacterium avium infections.

101 V) viremia and two cases of CMV disease (one pneumonitis and one enteritis).

102 Incidence of all-grade and grade 3 or higher pneumonitis and pneumonitis-related deaths.

103 changes associated with infection, including pneumonitis and pulmonary consolidation.

104 ranscript in AECs enhanced radiation-induced pneumonitis and pulmonary fibrosis, and increased the ex

105 ula in this murine model of hypersensitivity pneumonitis and pulmonary fibrosis.

106 Patients with interstitial pneumonitis and pulmonary hemosiderosis were also more l

107 ry low-birth-weight (VLBW) infants can cause pneumonitis and sepsislike illness.

108 Using a nonlymphopenic model of autoimmune pneumonitis and T(Reg) with known Ag specificity, in thi

109 aboons and was thought to be responsible for pneumonitis and the death of one animal.

110 ry fibrosis in experimental hypersensitivity pneumonitis and to determine the main inflammatory cell

111 rring diagnosis of desquamative interstitial pneumonitis and who were older than 10 years at the time

112 The impact on progression to pneumonitis and/or mortality of treating parainfluenza v

113 re consistent with subacute hypersensitivity pneumonitis (and IgG positive).

114 gnised expertise in chronic hypersensitivity pneumonitis, and further research and studies at other c

115 biopsy shows findings of usual interstitial pneumonitis, and he has no identifiable cause for pulmon

116 p of the spleen by macrophages, interstitial pneumonitis, and increased numbers of immature myeloid c

117 ntly diagnosed with chronic hypersensitivity pneumonitis, and most of these cases were attributed to

118 ing two with adrenal insufficiency, two with pneumonitis, and one with nephritis.

119 ointestinal ulcers, cholecystitis, radiation pneumonitis, and radioembolization-induced liver disease

120 Pneumonitis (any grade) was detected in 22 (8%) patients

121 The risk of pneumonitis appeared related to the ILV treated.

122 Patients with hypersensitivity pneumonitis are at risk of developing pulmonary fibrosis

123 alveolar macrophages and epithelial cells in pneumonitis areas.

124 r latent viral load, BMT mice develop severe pneumonitis associated with reduced oxygen saturation, f

125 There were four cases of pneumonitis at 4, 4, 7, and 9 months after treatment.

126 cterial aspiration pneumonia from aspiration pneumonitis based on quantitative bronchoalveolar lavage

127 ed as a result of autoimmune myocarditis and pneumonitis before developing renal disease or the syste

128 ferential susceptibility to hypersensitivity pneumonitis between C57BL/6 and DBA/2 mice.

129 -forming units (IFU) of C. trachomatis mouse pneumonitis biovar (MoPn) and were euthanized at 10 days

130 resolving genital infections with the mouse pneumonitis biovar of Chlamydia trachomatis (MoPn).

131 mice infected intravaginally with the mouse pneumonitis biovar of Chlamydia trachomatis became infer

132 GTs in mice during infection with the murine pneumonitis biovar of Chlamydia trachomatis.

133 hocytic alveolitis, lymphocytic interstitial pneumonitis, bronchoalveolar obliterans organizing pneum

134 ronavirus (SARS-CoV), primarily present with pneumonitis but may also develop hepatic, gastrointestin

135 atients had no evidence for hypersensitivity pneumonitis, but 70% of cases had a personal or family h

136 rine models of experimental hypersensitivity pneumonitis, but its role in the development of pulmonar

137 gnificantly protected from the hepatitis and pneumonitis, but not the dermatitis, induced by adoptive

138 fibrosis (IPF) and chronic hypersensitivity pneumonitis can be indistinguishable; the need to elimin

139 is model but was not effective in preventing pneumonitis caused by an H2N2 subtype.

140 role in the development of hypersensitivity pneumonitis caused by microbial Ags and that inhibition

141 of the current knowledge on hypersensitivity pneumonitis caused by the occupational environment and t

142 influenza A virus causes an acute, transient pneumonitis characterized by the massive infiltration of

143 urrent diagnosis of chronic hypersensitivity pneumonitis (cHP) involves considering a combination of

144 bined UCSF and UTSW chronic hypersensitivity pneumonitis cohort, we saw associations between extent o

145 copies/microg human DNA for 12 subjects with pneumonitis compared to 91 copies for 31 subjects withou

146 limited the rates of clinically significant pneumonitis, dose-limiting toxicity occurred and was dom

147 infections and occupational hypersensitivity pneumonitis due to metalworking fluid (MWF) exposures.

148 adverse effects, such as fibro-interstitial pneumonitis due to the acquisition of activated myofibro

149 The overall incidence of pneumonitis during PD-1 inhibitor monotherapy was 2.7% (

150 thought to have died from grade 5 radiation pneumonitis during the study; however, this adverse even

151 e found in incidence of acute skin reaction, pneumonitis, dyspnea, cough, dysphagia, or neutropenia.

152 rhoea, decreased appetite, hyponatremia, and pneumonitis (each in two [1%]) in those given pembrolizu

153 ell-characterized murine models of radiation pneumonitis/fibrosis to compare and contrast differentia

154 The risk of pneumonitis for the two cohorts combined was: 17% (four

155 luding: fatigue (five [4%] of 117 patients), pneumonitis (four [3%]), and diarrhoea (three [3%]).

156 ia (five [10%] and two [10%], respectively), pneumonitis (four [8%] and none, respectively), oedema (

157 terstitial pneumonia, 16 as hypersensitivity pneumonitis, four as sarcoidosis, four as respiratory br

158 ne toxic death (66 Gy) and 1 case of grade 4 pneumonitis (>66 Gy) were reported.

159 and 11 years) with desquamative interstitial pneumonitis had ABCA3 mutations identified on both allel

160 The prevalence of lymphocytic interstitial pneumonitis had also dropped significantly following int

161 he 20 patients with chronic hypersensitivity pneumonitis had histopathological features on surgical l

162 ressive agents, had no active non-infectious pneumonitis, had no uncontrolled thyroid dysfunction or

163 ents requiring mechanical ventilation due to pneumonitis have a particularly poor outcome, and our fi

164 h, colitis, hepatitis, endocrinopathies, and pneumonitis have been established.

165 netic studies in familial usual interstitial pneumonitis have been inconclusive.

166 duce IL-17A in experimental hypersensitivity pneumonitis have not yet been identified.

167 Hypersensitivity pneumonitis (HP) develops after inhalation of many diffe

168 Human cases of hypersensitivity pneumonitis (HP) have been reported among machinists for

169 Hypersensitivity pneumonitis (HP) is a complex syndrome resulting from re

170 Hypersensitivity pneumonitis (HP) is an inflammatory lung disease charact

171 Hypersensitivity pneumonitis (HP) is an inflammatory lung disease that de

172 re in patients with chronic hypersensitivity pneumonitis (HP) the computed tomographic (CT) imaging f

173 Hypersensitivity pneumonitis (HP), an inflammatory lung disease, develops

174 ns, fatigue, thrombocytopenia, noninfectious pneumonitis, hyperglycemia, and rash.

175 luded esophagitis in 14 v nine patients, and pneumonitis in 0 v 6 patients for HART and qdRT, respect

176 rminated early because of treatment-emergent pneumonitis in 18% of patients (severe in 11 of 12 cases

177 Final diagnosis: hypersensitivity pneumonitis in 47.3% (n = 513; exposure, 48.1% air coole

178 induce arthritis, ileitis, and interstitial pneumonitis in BALB/c ZAP70 (W163C)-mutant (SKG) mice vi

179 Hypersensitivity pneumonitis in children is an underrecognized form of im

180 is an opportunistic pathogen that can cause pneumonitis in immunodeficient people such as AIDS patie

181 ariable analyses demonstrated higher odds of pneumonitis in NSCLC for all-grade (odds ratio [OR], 1.4

182 ls, but not B cells, prevented hepatitis and pneumonitis in RAG(-/-) recipients of scurfy lymphocytes

183 15 Gy of x-rays to the thorax causes severe pneumonitis in rats by 6-8 wk.

184 treptococcus pneumoniae type 25 causes acute pneumonitis in rats.

185 locus was a significant risk factor for CMV pneumonitis in recipients exposed to CMV before transpla

186 We therefore examined the risk of pneumonitis in relation to lung dose-volume parameters.

187 n that excessive T cell activity can mediate pneumonitis in the setting of influenza infection, and d

188 Early prediction of radiation pneumonitis in time to initiate mitigation will benefit

189 nia, elevated lipase, hypophosphataemia, and pneumonitis in two (1%) patients each.

190 mouse model of experimental hypersensitivity pneumonitis in which IL-17A was inhibited or neutrophils

191 Mice died from an acute lymphocytic pneumonitis in which T and NK cells dominate a severe in

192 +) bone marrow cells induced myocarditis and pneumonitis in WT;MRL(+/+) mice, despite a dramatic up-r

193 plantation patients who develop interstitial pneumonitis include idiopathic pneumonia syndrome and br

194 red in 15 (5%) of 310 treated patients, with pneumonitis, increased aspartate aminotransferase, incre

195 of bleomycin-treated WT mice display: severe pneumonitis; increased generation of superoxide; vascula

196 HIV-1-induced interstitial pneumonitis (IP) is a serious complication of HIV-1 infe

197 rom patients with RA-associated interstitial pneumonitis (IP) were examined by immunohistochemistry.

198 rammed cell death 1 (PD-1) inhibitor-related pneumonitis is a rare but clinically serious and potenti

199 Bleomycin-induced pneumonitis is an acute rather than late effect of treat

200 Hypersensitivity pneumonitis is an environmental lung disease characteriz

201 Hypersensitivity pneumonitis is an interstitial lung disease that results

202 Chronic hypersensitivity pneumonitis is characterized by pulmonary inflammation a

203 greement for a diagnosis of hypersensitivity pneumonitis is low, highlighting an urgent need for stan

204 Radiation pneumonitis is reported in 5% to 15% of lung cancer pati

205 BLM-induced pneumonitis is the most feared, dose-limiting side effec

206 [0.37-0.49]); and fair for hypersensitivity pneumonitis (kappaw=0.29 [0.24-0.40]).

207 Other manifestations include eosinophilic pneumonitis, localized myositis, folliculitis, erythema

208 astatic pulmonary neoplasms, postobstructive pneumonitis, lung abscess, and occasionally empyema of m

209 ars]), and 192 with chronic hypersensitivity pneumonitis (men, 76; women, 116; median age, 66 years [

210 tion by a H3N2 subtype in a murine influenza pneumonitis model but was not effective in preventing pn

211 ding frames (ORFs) from C. trachomatis mouse pneumonitis (MoPn) genomic and plasmid DNA and tested it

212 eparation of the Chlamydia trachomatis mouse pneumonitis (MoPn) major outer membrane protein (MOMP) a

213 es (MAbs) to the Chlamydia trachomatis mouse pneumonitis (MoPn) major outer membrane protein (MOMP) w

214 eparation of the Chlamydia trachomatis mouse pneumonitis (MoPn) major outer membrane protein (MOMP),

215 rified and refolded the C. trachomatis mouse pneumonitis (MoPn) major outer membrane protein (MOMP).

216 ome sequences of Chlamydia trachomatis mouse pneumonitis (MoPn) strain Nigg (1 069 412 nt) and Chlamy

217 aths (5%) occurred on therapy as a result of pneumonitis (n = 1), stroke (n =1), and heart failure (n

218 Manifestations included pneumonitis (n = 7), myocarditis (n = 5), brain abscesse

219 ort, and grade 3 colitis (n=1 [6%]), grade 3 pneumonitis (n=1 [6%]), grade 3 fatigue (n=1 [6%]), grad

220 equent diagnosis of chronic hypersensitivity pneumonitis: nine patients had positive bronchial challe

221 r [7%]), diarrhoea (five [10%] vs one [2%]), pneumonitis (none vs five [9%]), stomatitis (none vs fiv

222 Pulmonary infections and pneumonitis occur frequently after hematopoietic stem ce

223 organizing pneumonia (BOOP) and interstitial pneumonitis occurred at 4 to 6 weeks, and 6 to 12 weeks,

224 Acute grade 2 pneumonitis occurred in 1 (2%) patient.

225 Grade 4+ pneumonitis occurred in 1% of those younger than 70 year

226 Late grades 2 and 3 pneumonitis occurred in 10 (16%) and 8 (12%), respective

227 Although grade 2 radiation pneumonitis occurred in five patients, grade 3 radiation

228 Symptomatic pneumonitis occurred in one patient (2.6%).

229 occurred in five patients, grade 3 radiation pneumonitis occurred in only two.

230 related to either drug, and one death due to pneumonitis occurred in the erlotinib plus cabozantinib

231 s in the everolimus group, of whom eight had pneumonitis of grade 3 severity.

232 Occupational hypersensitivity pneumonitis (OHP) is an immunologic lung disease resulti

233 rejection (AR), and/or cytomegalovirus (CMV) pneumonitis on current or prior biopsies.

234 tigue (one patient given 30 mg/day), grade 3 pneumonitis (one given 60 mg/day), and grade 4 thrombocy

235 rterial injury (one), neutropenia (one), and pneumonitis (one).

236 ts of patients with chronic hypersensitivity pneumonitis, one from the University of California San F

237 There was one grade 5 adverse event (AE) of pneumonitis, one grade 4 thrombosis, and nine other grad

238 sy that was consistent with hypersensitivity pneumonitis; one was IgG positive plus had greater than

239 Drug-related interstitial pneumonitis or cardiac dysfunction associated with other

240 t of severe clinical manifestations, such as pneumonitis or eye complications; (ii) patients with a p

241 Dose-limiting pneumonitis or myelosuppression was observed in three of

242 A definitive diagnosis of aspiration pneumonitis or pneumonia is challenging to make.

243 .60-5.08; P < .001) and in RCC for all-grade pneumonitis (OR, 1.59; 95% CI, 1.32-1.92; P < .001) comp

244 , 1.08-1.89; P = .005) and grade 3 or higher pneumonitis (OR, 2.85; 95% CI, 1.60-5.08; P < .001) and

245 , 1.69-2.50; P < .001) and grade 3 or higher pneumonitis (OR, 2.86; 95% CI, 1.79- 4.35; P < .001).

246 ng corrected QT interval (QTc) prolongation, pneumonitis, or neuropathic pain.

247 e of 192 (4.7%) had chronic hypersensitivity pneumonitis (P < .001), and 27 of 244 (11.1%) had nonspe

248 ction (p = 0.0126) and cytomegalovirus (CMV) pneumonitis (p = 0.0358).

249 ically latent period, the intermediate acute pneumonitis phase and the later fibrotic stage.

250 dnTGFbetaRII are largely protected from the pneumonitis phenotype, whereas mice with CD11c-dnTGFbeta

251 G at the onset of clinical disease, subacute pneumonitis, rapid onset of diffuse alveolar edema in th

252 (1.5% vs 0.2%; P = .001) in melanoma, with 1 pneumonitis-related death during combination therapy.

253 Four pneumonitis-related deaths were observed in patients wit

254 -grade and grade 3 or higher pneumonitis and pneumonitis-related deaths.

255 al lung diseases, including hypersensitivity pneumonitis, respiratory bronchiolitis-associated inters

256 t reported pediatric cases, hypersensitivity pneumonitis results from exposure to avian antigens, but

257 20 was associated with increased >/= grade 3 pneumonitis risk on multivariable analysis ( P = .026).

258 r associations with chronic hypersensitivity pneumonitis risk, survival, and clinical, radiographic,

259 he incidence of grade 3 or greater radiation pneumonitis (RP).

260 ent doses of the Chlamydia trachomatis mouse pneumonitis serovar.

261 ern consistent with chronic hypersensitivity pneumonitis); seven were IgG positive plus had histopath

262 diagnosed with summer-type hypersensitivity pneumonitis (SHP).

263 combination between the C. trachomatis mouse pneumonitis strain and the C. pneumoniae horse N16 strai

264 ritoneal macrophages infected with the mouse pneumonitis strain of C. trachomatis.

265 al in patients with chronic hypersensitivity pneumonitis suggest shared pathobiology with IPF, and mi

266 cterium avium complex, lymphoid interstitial pneumonitis, systemic fungal infection, cytomegalovirus

267 50 in patients with chronic hypersensitivity pneumonitis than in healthy controls (24.4% in UCSF and

268 In a mouse model of hypersensitivity pneumonitis that progresses to lung fibrosis upon repeat

269 we have shown in a model of hypersensitivity pneumonitis that Th1-biased C57BL/6 mice are susceptible

270 Consequences range from subclinical pneumonitis to respiratory failure, with fibrosis develo

271 genetically identical mice varied from mild pneumonitis to severe acute lung injury with extensive p

272 creased lipase (three [8%] and no patients), pneumonitis (two [5%] and one [3%] patients), adrenal in

273 s before bronchoscopy in those subjects with pneumonitis versus 0 days in those without (P=0.004).

274 from both models surviving high-fat feeding, pneumonitis was absent, but aortic atherosclerosis was 2

275 Delayed-onset CMV pneumonitis was associated with inpatient death longer t

276 Minimal pneumonitis was associated with the lung infection, but

277 nce: The incidence of PD-1 inhibitor-related pneumonitis was higher in NSCLC and RCC and during combi

278 These results suggest that delayed-onset CMV pneumonitis was independently associated with an increas

279 Hypersensitivity pneumonitis was induced in C57BL/6 wild-type or recombin

280 Pneumonitis was more frequent during combination therapy

281 No grade 3 pneumonitis was observed and an MTD for acute toxicity w

282 No clinically significant noninfectious pneumonitis was observed.

283 ptomatic cardiotoxicity, and no interstitial pneumonitis was reported.

284 By day 7, histopathologic evidence of pneumonitis was seen in the lungs when viral clearance o

285 Hypersensitivity pneumonitis was the most common new-onset ILD in India,

286 found that the severity of hypersensitivity pneumonitis was unaffected by vancomycin, but increased

287 Toxicity, especially myelosuppression and pneumonitis, was more pronounced in the elderly patients

288 ith ALI and lungs from mice with LPS-induced pneumonitis, we found that pulmonary SDF-1 expression in

289 established murine model of hypersensitivity pneumonitis, we repeatedly exposed C57BL/6 mice to Sacch

290 ocytic bronchiolitis, BOOP, and interstitial pneumonitis were directly associated with the developmen

291 s of veno-occlusive disease and interstitial pneumonitis were high at 20%.

292 interstitial pneumonia and hypersensitivity pneumonitis, were reclassified as IPF.

293 in severities in alveolitis and interstitial pneumonitis when each of the three variants was compared

294 and head and neck cancer develop aspiration pneumonitis, which is usually caused by organisms living

295 (IPF) or chronic (fibrotic) hypersensitivity pneumonitis, which suggests these disorders share risk f

296 Three patients died of pneumonitis while in the study.

297 Incidence of pneumonitis with temsirolimus/bevacizumab was 4.8%, most

298 g to patients' stratified risk for radiation pneumonitis with total RT doses ranging from 57 to 85.5

299 zed by viremia in the presence or absence of pneumonitis, with viral loads higher in the lung airways

300 lous granulomas, and in the nongranulomatous pneumonitis zone.